{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T10:50:27Z","timestamp":1780915827268,"version":"3.54.1"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2018,4,12]],"date-time":"2018-04-12T00:00:00Z","timestamp":1523491200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100001809","name":"the National Nature Science Foundation of China","doi-asserted-by":"crossref","award":["81202114"],"award-info":[{"award-number":["81202114"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001809","name":"the National Nature Science Foundation of China","doi-asserted-by":"crossref","award":["81301879"],"award-info":[{"award-number":["81301879"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001809","name":"the National Nature Science Foundation of China","doi-asserted-by":"crossref","award":["81301874"],"award-info":[{"award-number":["81301874"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"name":"the National Science Foundation of Beijing","award":["7132051"],"award-info":[{"award-number":["7132051"]}]},{"name":"the General Program, Research Fund for the Doctoral Program of Higher Education","award":["2012001120135"],"award-info":[{"award-number":["2012001120135"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Virchows Arch"],"published-print":{"date-parts":[[2018,5]]},"DOI":"10.1007\/s00428-018-2357-6","type":"journal-article","created":{"date-parts":[[2018,4,12]],"date-time":"2018-04-12T16:00:20Z","timestamp":1523548820000},"page":"779-787","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":38,"title":["In papillary thyroid carcinoma, expression by immunohistochemistry of BRAF V600E, PD-L1, and PD-1 is closely related"],"prefix":"10.1007","volume":"472","author":[{"given":"Yanhua","family":"Bai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ting","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaozheng","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongfeng","family":"Niu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinqiang","family":"Ji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qin","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhongwu","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kennichi","family":"Kakudo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,4,12]]},"reference":[{"key":"2357_CR1","doi-asserted-by":"crossref","first-page":"1908","DOI":"10.1111\/j.1349-7006.2008.00908.x","volume":"99","author":"Y Bai","year":"2008","unstructured":"Bai Y, Kakudo K, Li Y, Liu Z, Ozaki T, Ito Y, Kihara M, Miyauchi A (2008) Subclassification of non-solid-type papillary thyroid carcinoma identification of high-risk group in common type. Cancer Sci 99:1908\u20131915","journal-title":"Cancer Sci"},{"key":"2357_CR2","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1002\/1097-0142(19850215)55:4<805::AID-CNCR2820550419>3.0.CO;2-Z","volume":"55","author":"ML Carcangiu","year":"1985","unstructured":"Carcangiu ML, Zampi G, Pupi A, Castagnoli A, Rosai J (1985) Papillary carcinoma of the thyroid. A clinicopathologic study of 241 cases treated at the University of Florence, Italy. Cancer 55:805\u2013828","journal-title":"Cancer"},{"key":"2357_CR3","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1677\/erc.1.0978","volume":"12","author":"M Xing","year":"2005","unstructured":"Xing M (2005) BRAF mutation in thyroid cancer. Endocr Relat Cancer 12:245\u2013262","journal-title":"Endocr Relat Cancer"},{"key":"2357_CR4","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1016\/j.canlet.2013.02.033","volume":"335","author":"P Baquero","year":"2013","unstructured":"Baquero P, Sanchez-Hernandez I, Jimenez-Mora E, Orgaz JL, Jimenez B, Chiloeches A (2013) (V600E) BRAF promotes invasiveness of thyroid cancer cells by decreasing E-cadherin expression through a Snail-dependent mechanism. Cancer Lett 335:232\u2013241","journal-title":"Cancer Lett"},{"key":"2357_CR5","first-page":"1454","volume":"63","author":"ET Kimura","year":"2003","unstructured":"Kimura ET, Nikiforova MN, Zhu Z, Knauf JA, Nikiforov YE, Fagin JA (2003) High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET\/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma. Cancer Res 63:1454\u20131457","journal-title":"Cancer Res"},{"key":"2357_CR6","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1126\/science.1133427","volume":"314","author":"T Sj\u00f6blom","year":"2006","unstructured":"Sj\u00f6blom T, Jones S, Wood LD, Parsons DW, Lin J, Barber TD, Mandelker D, Leary RJ, Ptak J, Silliman N, Szabo S, Buckhaults P, Farrell C, Meeh P, Markowitz SD, Willis J, Dawson D, Willson JK, Gazdar AF, Hartigan J, Wu L, Liu C, Parmigiani G, Park BH, Bachman KE, Papadopoulos N, Vogelstein B, Kinzler KW, Velculescu VE (2006) The consensus coding sequences of human breast and colorectal cancers. Science 314:268\u2013274","journal-title":"Science"},{"key":"2357_CR7","doi-asserted-by":"publisher","first-page":"12293","DOI":"10.1073\/pnas.192461099","volume":"99","author":"Y Iwai","year":"2002","unstructured":"Iwai Y, Ishida M, Tanaka Y, Okazaki T, Honjo T, Minato N (2002) Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade. Proc Natl Acad Sci U S A 99:12293\u201312297","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2357_CR8","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1038\/nm730","volume":"8","author":"H Dong","year":"2002","unstructured":"Dong H, Strome SE, Salomao DR, Tamura H, Hirano F, Flies DB, Roche PC, Lu J, Zhu G, Tamada K, Lennon VA, Celis E, Chen L (2002) Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med 8:793\u2013800","journal-title":"Nat Med"},{"key":"2357_CR9","doi-asserted-by":"publisher","first-page":"127ra37","DOI":"10.1126\/scitranslmed.3003689","volume":"4","author":"JM Taube","year":"2012","unstructured":"Taube JM, Anders RA, Young GD, Xu H, Sharma R, McMiller TL, Chen S, Klein AP, Pardoll DM, Topalian SL, Chen L (2012) Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape. Sci Transl Med 4:127ra37","journal-title":"Sci Transl Med"},{"key":"2357_CR10","doi-asserted-by":"publisher","first-page":"2455","DOI":"10.1056\/NEJMoa1200694","volume":"366","author":"JR Brahmer","year":"2012","unstructured":"Brahmer JR, Tykodi SS, Chow LQ, Hwu WJ, Topalian SL, Hwu P, Drake CG, Camacho LH, Kauh J, Odunsi K, Pitot HC, Hamid O, Bhatia S, Martins R, Eaton K, Chen S, Salay TM, Alaparthy S, Grosso JF, Korman AJ, Parker SM, Agrawal S, Goldberg SM, Pardoll DM, Gupta A, Wigginton JM (2012) Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 366:2455\u20132465","journal-title":"N Engl J Med"},{"key":"2357_CR11","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1007\/s00428-016-1910-4","volume":"468","author":"M Ilie","year":"2016","unstructured":"Ilie M, Hofman V, Dietel M, Soria JC, Hofman P (2016) Assessment of the PD-L1 status by immunohistochemistry: challenges and perspectives for therapeutic strategies in lung cancer patients. Virchows Arch 468:511\u2013525","journal-title":"Virchows Arch"},{"key":"2357_CR12","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1016\/j.ctrv.2014.12.013","volume":"41","author":"F Massari","year":"2015","unstructured":"Massari F, Santoni M, Ciccarese C, Santini D, Alfieri S, Martignoni G, Brunelli M, Piva F, Berardi R, Montironi R, Porta C, Cascinu S, Tortora G (2015) PD-1 blockade therapy in renal cell carcinoma: current studies and future promises. Cancer Treat Rev 41:114\u2013121","journal-title":"Cancer Treat Rev"},{"key":"2357_CR13","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1158\/1078-0432.CCR-12-2063","volume":"19","author":"M Sznol","year":"2013","unstructured":"Sznol M, Chen L (2013) Antagonist antibodies to PD-1 and B7-H1 (PD-L1) in the treatment of advanced human cancer. Clin Cancer Res 19:1021\u20131034","journal-title":"Clin Cancer Res"},{"key":"2357_CR14","doi-asserted-by":"crossref","first-page":"73068","DOI":"10.18632\/oncotarget.12230","volume":"7","author":"T Zhang","year":"2016","unstructured":"Zhang T, Xie J, Arai S, Wang L, Shi X, Shi N, Ma F, Chen S, Huang L, Yang L, Ma W, Zhang B, Han W, Xia J, Chen H, Zhang Y (2016) The efficacy and safety of anti-PD-1\/PD-L1 antibodies for treatment of advanced or refractory cancers: a meta-analysis. Oncotarget 7:73068\u201373079","journal-title":"Oncotarget"},{"key":"2357_CR15","doi-asserted-by":"publisher","first-page":"2443","DOI":"10.1056\/NEJMoa1200690","volume":"366","author":"SL Topalian","year":"2012","unstructured":"Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, Powderly JD, Carvajal RD, Sosman JA, Atkins MB, Leming PD, Spigel DR, Antonia SJ, Horn L, Drake CG, Pardoll DM, Chen L, Sharfman WH, Anders RA, Taube JM, McMiller TL, Xu H, Korman AJ, Jure-Kunkel M, Agrawal S, McDonald D, Kollia GD, Gupta A, Wigginton JM, Sznol M (2012) Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 366:2443\u20132454","journal-title":"N Engl J Med"},{"key":"2357_CR16","doi-asserted-by":"publisher","first-page":"2139","DOI":"10.1158\/0008-5472.CAN-15-0255","volume":"75","author":"MW Teng","year":"2015","unstructured":"Teng MW, Ngiow SF, Ribas A, Smyth MJ (2015) Classifying cancers based on T-cell infiltration and PD-L1. Cancer Res 75:2139\u20132145","journal-title":"Cancer Res"},{"key":"2357_CR17","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.canlet.2015.10.009","volume":"370","author":"H Tang","year":"2016","unstructured":"Tang H, Qiao J, Fu YX (2016) Immunotherapy and tumor microenvironment. Cancer Lett 370:85\u201390","journal-title":"Cancer Lett"},{"key":"2357_CR18","doi-asserted-by":"publisher","first-page":"4885","DOI":"10.1158\/0008-5472.CAN-09-0727","volume":"69","author":"JC Ricarte-Filho","year":"2009","unstructured":"Ricarte-Filho JC, Ryder M, Chitale DA, Rivera M, Heguy A, Ladanyi M, Janakiraman M, Solit D, Knauf JA, Tuttle RM, Ghossein RA, Fagin JA (2009) Mutational profile of advanced primary and metastatic radioactive iodine-refractory thyroid cancers reveals distinct pathogenetic roles for BRAF, PIK3CA, and AKT1. Cancer Res 69:4885\u20134893","journal-title":"Cancer Res"},{"key":"2357_CR19","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1038\/nrc3431","volume":"13","author":"M Xing","year":"2013","unstructured":"Xing M (2013) Molecular pathogenesis and mechanisms of thyroid cancer. Nat Rev Cancer 13:184\u2013199","journal-title":"Nat Rev Cancer"},{"key":"2357_CR20","doi-asserted-by":"crossref","first-page":"32318","DOI":"10.18632\/oncotarget.8698","volume":"31","author":"S Chowdhury","year":"2016","unstructured":"Chowdhury S, Veyhl J, Jessa F, Polyakova O, Alenzi A, MacMillan C, Ralhan R, Walfish PG (2016) Programmed death-ligand 1 overexpression is a prognostic marker for aggressive papillary thyroid cancer and its variants. Oncotarget 31:32318\u201332328","journal-title":"Oncotarget"},{"key":"2357_CR21","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1530\/ERC-16-0421","volume":"24","author":"S Ahn","year":"2017","unstructured":"Ahn S, Kim TH, Kim SW, Ki CS, Jang HW, Kim JS, Kim JH, Choe JH, Shin JH, Hahn SY, Oh YL, Chung JH (2017) Comprehensive screening for PD-L1 expression in thyroid cancer. Endocr Relat Cancer 24:97\u2013106","journal-title":"Endocr Relat Cancer"},{"key":"2357_CR22","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1530\/ERC-12-0313","volume":"20","author":"LL Cunha","year":"2013","unstructured":"Cunha LL, Marcello MA, Morari EC, Nonogaki S, Conte FF, Gerhard R, Soares FA, Vassallo J, Ward LS (2013) Differentiated thyroid carcinomas may elude the immune system by B7H1 upregulation. Endocr Relat Cancer 20:103\u2013110","journal-title":"Endocr Relat Cancer"},{"key":"2357_CR23","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1007\/s12253-014-9876-5","volume":"21","author":"H Wu","year":"2015","unstructured":"Wu H, Sun Y, Ye H, Yang S, Lee SL, de las Morenas A (2015) Anaplastic thyroid cancer: outcome and the mutation\/expression profiles of potential targets. Pathol Oncol Res 21:695\u2013701","journal-title":"Pathol Oncol Res"},{"key":"2357_CR24","doi-asserted-by":"publisher","first-page":"2863","DOI":"10.1210\/jc.2015-4227","volume":"101","author":"JJ Bastman","year":"2016","unstructured":"Bastman JJ, Serracino HS, Zhu Y, Koenig MR, Mateescu V, Sams SB, Davies KD, Raeburn CD, McIntyre RC Jr, Haugen BR, French JD (2016) Tumor-infiltrating T cells and the PD-1 checkpoint pathway in advanced differentiated and anaplastic thyroid cancer. J Clin Endocrinol Metab 101:2863\u20132873","journal-title":"J Clin Endocrinol Metab"},{"key":"2357_CR25","doi-asserted-by":"publisher","first-page":"3446","DOI":"10.1158\/1078-0432.CCR-13-2797","volume":"20","author":"M Atefi","year":"2014","unstructured":"Atefi M, Avramis E, Lassen A, Wong DJ, Robert L, Foulad D, Cerniglia M, Titz B, Chodon T, Graeber TG, Comin-Anduix B, Ribas A (2014) Effects of MAPK and PI3K pathways on PD-L1 expression in melanoma. Clin Cancer Res 20:3446\u20133457","journal-title":"Clin Cancer Res"},{"key":"2357_CR26","doi-asserted-by":"publisher","first-page":"17194","DOI":"10.18632\/oncotarget.7839","volume":"7","author":"E Brauner","year":"2016","unstructured":"Brauner E, Gunda V, Vanden Borre P, Zurakowski D, Kim YS, Dennett KV, Amin S, Freeman GJ, Parangi S (2016) Combining BRAF inhibitor and anti PD-L1 antibody dramatically improves tumor regression and anti tumor immunity in an immunocompetent murine model of anaplastic thyroid cancer. Oncotarget 7:17194\u201317211","journal-title":"Oncotarget"},{"key":"2357_CR27","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1016\/j.ejso.2006.09.024","volume":"33","author":"H Zuo","year":"2007","unstructured":"Zuo H, Tang W, Yasuoka H, Nakamura Y, Ito Y, Miyauchi A, Kakudo K (2007) A review of 227 cases of small papillary thyroid carcinoma. Eur J Surg Oncol 33:370\u2013375","journal-title":"Eur J Surg Oncol"},{"key":"2357_CR28","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1038\/modpathol.2009.38","volume":"22","author":"Y Bai","year":"2009","unstructured":"Bai Y, Zhou G, Nakamura M, Ozaki T, Mori I, Taniguchi E, Miyauchi A, Ito Y, Kakudo K (2009) Survival impact of psammoma body, stromal calcification, and bone formation in papillary thyroid carcinoma. Mod Pathol 22:887\u2013894","journal-title":"Mod Pathol"},{"key":"2357_CR29","first-page":"15072","volume":"8","author":"J Sun","year":"2015","unstructured":"Sun J, Zhang J, Lu J, Gao J, Lu T, Ren X, Duan H, Liang Z (2015) Immunohistochemistry is highly sensitive and specific for detecting the BRAF V600E mutation in papillary thyroid carcinoma. Int J Clin Exp Pathol 8:15072\u201315078","journal-title":"Int J Clin Exp Pathol"},{"key":"2357_CR30","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1007\/s12022-015-9374-7","volume":"26","author":"JS Pyo","year":"2015","unstructured":"Pyo JS, Sohn JH, Kang G (2015) BRAF immunohistochemistry using clone VE1 is strongly concordant with BRAF (V600E) mutation test in papillary thyroid carcinoma. Endocr Pathol 26:211\u2013217","journal-title":"Endocr Pathol"},{"key":"2357_CR31","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1111\/pin.12215","volume":"64","author":"H Liu","year":"2014","unstructured":"Liu H, Li Z, Wang Y, Feng Q, Si L, Cui C, Guo J, Xue W (2014) Immunohistochemical detection of the BRAF V600E mutation in melanoma patients with monoclonal antibody VE1. Pathol Int 64:601\u2013606","journal-title":"Pathol Int"},{"key":"2357_CR32","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1097\/PAS.0b013e318246b527","volume":"36","author":"O Koperek","year":"2012","unstructured":"Koperek O, Kornauth C, Capper D, Berghoff AS, Asari R, Niederle B, von Deimling A, Birner P, Preusser M (2012) Immunohistochemical detection of the BRAF V600E-mutated protein in papillary thyroid carcinoma. Am J Surg Pathol 36:844\u2013850","journal-title":"Am J Surg Pathol"},{"key":"2357_CR33","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1016\/j.humpath.2016.05.012","volume":"55","author":"Z Li","year":"2016","unstructured":"Li Z, Lai Y, Sun L, Zhang X, Liu R, Feng G, Zhou L, Jia L, Huang X, Kang Q, Lin D, Gao J, Shen L (2016) PD-L1 expression is associated with massive lymphocyte infiltration and histology in gastric cancer. Hum Pathol 55:182\u2013189","journal-title":"Hum Pathol"},{"key":"2357_CR34","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1111\/his.13230","volume":"71","author":"K Zwaenepoel","year":"2017","unstructured":"Zwaenepoel K, Jacobs J, De Meulenaere A, Silence K, Smits E, Siozopoulou V, Hauben E, Rolfo C, Rottey S, Pauwels P (2017) CD70 and PD-L1 in anaplastic thyroid cancer-promising targets for immunotherapy. Histopathology 71:357\u2013365","journal-title":"Histopathology"},{"key":"2357_CR35","doi-asserted-by":"publisher","first-page":"1943","DOI":"10.1210\/jc.2016-3756","volume":"102","author":"AV Chintakuntlawar","year":"2017","unstructured":"Chintakuntlawar AV, Rumilla KM, Smith CY, Jenkins SM, Foote RL, Kasperbauer JL, Morris JC, Ryder M, Alsidawi S, Hilger C, Bible KC (2017) Expression of PD-1 and PD-L1 in anaplastic thyroid cancer patients treated with multimodal therapy: results from a retrospective study. J Clin Endocrinol Metab 102:1943\u20131950","journal-title":"J Clin Endocrinol Metab"},{"key":"2357_CR36","doi-asserted-by":"publisher","first-page":"1385","DOI":"10.1089\/thy.2014.0134","volume":"24","author":"TE Angell","year":"2014","unstructured":"Angell TE, Lechner MG, Jang JK, Correa AJ, LoPresti JS, Epstein AL (2014) BRAF V600E in papillary thyroid carcinoma is associated with increased programmed death ligand 1 expression and suppressive immune cell infiltration. Thyroid 24:1385\u20131393","journal-title":"Thyroid"},{"key":"2357_CR37","doi-asserted-by":"publisher","first-page":"6964","DOI":"10.1158\/0008-5472.CAN-16-0258","volume":"76","author":"CA Clark","year":"2016","unstructured":"Clark CA, Gupta HB, Sareddy G, Pandeswara S, Lao S, Yuan B, Drerup JM, Padron A, Conejo-Garcia J, Murthy K, Liu Y, Turk MJ, Thedieck K, Hurez V, Li R, Vadlamudi R, Curiel TJ (2016) Tumor-intrinsic PD-L1 signals regulate cell growth, pathogenesis, and autophagy in ovarian cancer and melanoma. Cancer Res 76:6964\u20136974","journal-title":"Cancer Res"}],"container-title":["Virchows Archiv"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00428-018-2357-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00428-018-2357-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00428-018-2357-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,5]],"date-time":"2024-07-05T23:24:50Z","timestamp":1720221890000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00428-018-2357-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,4,12]]},"references-count":37,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2018,5]]}},"alternative-id":["2357"],"URL":"https:\/\/doi.org\/10.1007\/s00428-018-2357-6","relation":{},"ISSN":["0945-6317","1432-2307"],"issn-type":[{"value":"0945-6317","type":"print"},{"value":"1432-2307","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,4,12]]},"assertion":[{"value":"15 January 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 November 2017","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 April 2018","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 April 2018","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}]}}